ORKA – oruka therapeutics, inc. (US:NASDAQ)

News

Oruka Therapeutics, Inc. (NASDAQ: ORKA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody [Yahoo! Finance]
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) [Yahoo! Finance]
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com